Adocia (XPAR:ADOC) Accounts Payable : €2.46 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Adocia Accounts Payable?

Adocia's Accounts Payable for the quarter that ended in Dec. 2023 was €2.46 Mil.

Adocia's quarterly Accounts Payable increased from Dec. 2022 (€3.76 Mil) to Jun. 2023 (€3.82 Mil) but then declined from Jun. 2023 (€3.82 Mil) to Dec. 2023 (€2.46 Mil).

Adocia's annual Accounts Payable increased from Dec. 2021 (€1.09 Mil) to Dec. 2022 (€3.76 Mil) but then declined from Dec. 2022 (€3.76 Mil) to Dec. 2023 (€2.46 Mil).

Adocia Accounts Payable Historical Data

The historical data trend for Adocia's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adocia Accounts Payable Chart

Adocia Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

2.65

2.43

1.09

3.76

2.46

Adocia Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable	Get a 7-Day Free Trial															1.09	3.76	3.76	3.82	2.46

Adocia Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Adocia Accounts Payable Related Terms

Thank you for viewing the detailed overview of Adocia's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Adocia (XPAR:ADOC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adocia (XPAR:ADOC) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

A89:Germany

Address

115 Avenue Lacassagne, Lyon, FRA, 69003

Website

https://www.adocia.com

Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.